Abstract:Introduction: Breast cancer is the most common cancer in women in the U.S. As survival in breast cancer has improved, one of the key clinical problems in breast cancer survivors is the increased risk of second cancers. Over half (55%) of breast cancer survivors die from second cancers, of which lung cancer (i.e., second primary lung cancer [SPLC]) is the most frequent type. While smoking and radiotherapy have been identified as the risk factors for SPLC among breast cancer survivors, other potential factors (e.g., comorbidity, and medication) have been underexamined. In addition, women in general have shown higher susceptibility to smoking-induced lung cancer than men, suggesting the potential involvement of hormonal factors; however, the effect of hormone replacement therapy (HRT) on lung cancer risk has been controversial and has never been examined among breast cancer survivors. We aimed to examine the factors associated with SPLC risk among breast cancer survivors, focusing on the effect of HRT and its interaction with smoking. We also explored the potential of tailored risk-based management of SPLC for breast cancer survivors. Methods: We identified 5,552 patients diagnosed with breast cancer in 1993-2014 from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. SPLC was defined as a newly diagnosed lung cancer after 6 months from the time of breast cancer diagnosis. We applied multivariable cause-specific Cox regression to identify new factors associated with SPLC risk, adjusting for multiple testing using the Bonferroni method (P<0.01). We developed a prediction model to predict a 5-year risk of SPLC among breast cancer survivors that included both ever- and never-smokers and evaluated the predictive accuracy vs. a well-established lung cancer risk model, PLCOm2012, that was developed for a cancer-free population who ever smoked. Results: Of 5,552 patients, 89 (1.6%) developed SPLC over 102,545 person-years. Several factors measured at baseline in PLCO were significantly associated with SPLC risk among breast cancer survivors, including liver comorbidity (Hazard Ratio [HR] 3.28; P<.001), prior history of other cancer (HR 2.02; P=0.01), and regular use of ibuprofen (HR 0.52; P=0.01). In addition, ever-use of HRT was associated with a 51% reduction in SPLC risk (HR 0.49; P=0.001). The effect of active smoking on SPLC risk vs non-active smoking (HR 7.09; P<.001) was validated in PLCO. Notably, the effect of active smoking was intensified among ever-HRT users (HR=10.5; P<.001) vs. never-HRT users (HR 4.1; P<.001), thus showing a significant interaction (Pinteraction=0.003). The prediction model for SPLC risk was validated through bootstrap and demonstrated higher discrimination (AUC 0.83) vs. the PLCOm2012 model (AUC 0.79). Conclusions: In a large prospective cohort of breast cancer survivors, smoking and HRT use showed a significant interaction on SPLC risk. The prediction model for SPLC could identify high-risk survivors for SPLC for tailored surveillance to improve the management of breast cancer survivors. Citation Format: Eunji Choi, Justin Lee, Julie T. Wu, Heather A. Wakelee, Lidia Schapira, Allison W. Kurian, Summer S. Han. Risk factors for second primary lung cancer among breast cancer survivors. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): nr P055.

Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States

Abstract LB151: Association of radiotherapy with the risk of subtype-specific lung cancer among breast cancer survivors in the United States

Association Between Radiotherapy and Risk of Second Primary Malignancies in Patients with Resectable Lung Cancer: a Population-Based Study

Impact of radiotherapy on second primary lung cancer incidence and survival in esophageal cancer survivors

Risk of Second Primary Cancers among Long-Term Survivors of Breast Cancer

Association between radiotherapy and the risk of second primary malignancies in breast cancer patients with different estrogen receptor statuses

Radiotherapy and Increased Risk of Second Primary Cancers in Breast Cancer Survivors: an Epidemiological and Large Cohort Study

Abstract P055: Risk factors for second primary lung cancer among breast cancer survivors

Risk Factors and Specific Cancer Types of Second Primary Malignancies in Patients with Breast Cancer Receiving Adjuvant Radiotherapy: a Case-Control Cohort Study Based on the SEER Database.

Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study

Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening

Radiation Therapy Changed the Second Malignancy Pattern in Rectal Cancer Survivors.

Abstract 77: Genetic Variations in the Stem Cell Pathway Predict for Toxicity Following Radiotherapy in Lung Cancer.

Elevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIA Breast Cancer.

A retrospective study on the impact of radiotherapy on the survival outcomes of small cell lung cancer patients based on the SEER database

Risk and prognosis of secondary lung cancer after radiation therapy for thoracic malignancies

Abstract 4582: Genome-wide Association Study of Toxicity Following Definitive Radiotherapy in Non-Small Cell Lung Cancer Patients.

Second Primary Lung Cancer after Breast Cancer: A Population-Based Study of 6,269 Women

Prognosis And Risk Factors Of Radiation-Induced Lymphopenia In Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy

Radiation-Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative Radiation Dose Response and Modification of Treatment Effects

Simple Clinical Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy In Lung Cancer: A Pooled Analysis Of 70 Studies